An open label international multi-center phase 2 activity and safety study of SU011248 [sunitinib] in patients with unresectable hepatocellular carcinoma.
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Sunitinib (Primary)
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 17 Dec 2009 Actual patient number (37) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.